INMB

Business Context and Reporting Period

Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended June 30, 2025
Business Overview: A clinical-stage biotechnology company focused on treating diseases involving innate immune dysfunction. Key product platforms include DN-TNF (XPro for Alzheimer's), CORDStrom (for RDEB), and INKmune (for cancer). The company is a smaller reporting company with no commercial revenue to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Impairment Charge: The company recorded a non-cash impairment charge of $16.5 million related to acquired in-process research and development (IPR&D) intangible assets. This was triggered by the failure of the Phase 2 clinical trial for XPro (Alzheimer's candidate) to meet its primary endpoint and the decision to halt immediate development plans due to resource constraints.
• Net Loss Increase: Net loss increased by approximately $13.4 million year-over-year, primarily driven by the $16.5 million impairment charge, partially offset by lower R&D and G&A expenses.
• Capital Raises: Financing activities improved significantly. The company raised approximately $27.5 million in net proceeds during the six months ended June 30, 2025, compared to $10.5 million in the prior year period. This included a registered direct offering of $18.9 million (gross) in June 2025 and ATM sales of approximately $10.1 million (net).
• Expense Reductions: R&D expenses decreased by $2.3 million and G&A expenses decreased by $0.6 million compared to the prior year, largely due to the completion of the XPro Phase 2 trial and reduced stock-based compensation.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With cash of $33.4 million, the company projects insufficient liquidity to sustain operations for one year following the issuance of these financial statements.
• Product Pipeline Updates:
  • XPro (Alzheimer's): Phase 2 trial failed primary endpoints in the overall population but showed potential signals in a pre-specified enriched subgroup. Development is paused pending a partnership.
  • CORDStrom (RDEB): Received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the FDA. Plans to submit a Biologics License Application (BLA) in 2026.
  • INKmune (Cancer): Phase II trial in metastatic castrate-resistant prostate cancer is ongoing.
• Executive Leadership Changes: On August 4, 2025, Dr. Raymond J. Tesi resigned as President, CEO, and Chairman. David J. Moss was appointed as the new President and CEO, and J. Kelly Ganjei was appointed Chairman. Cory Ellspermann was appointed Interim CFO.
• Legal Dispute: An ongoing dispute with a vendor involves approximately $1.6 million in outstanding invoices. The company has recorded only $0.2 million as a liability, believing the remaining $1.4 million was invoiced erroneously.

Investor Verification Checklist

• Liquidity Runway: Verify the specific timeline for cash depletion and the status of any new financing discussions given the "substantial doubt" disclosure.
• XPro Subgroup Data: Review the detailed statistical analysis of the "enriched subgroup" in the XPro Phase 2 trial to assess the validity of the potential signal and the likelihood of securing a development partner.
• Vendor Dispute Resolution: Monitor the status of the $1.4 million disputed invoice to determine if it will result in future legal costs or liability recognition.
• Regulatory Milestones: Track the timeline for the CORDStrom BLA submission and the potential value of the Priority Review Voucher (PRV) if approved by September 2026.
• Dilution Risk: Assess the impact of future equity raises required to fund operations, given the current cash burn rate and lack of revenue.